Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Best disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,660 result(s) found for: Best disease. Displaying page 1 of 133.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002584-33 Sponsor Protocol Number: CINC424C2301 Start Date*: 2017-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran...
    Medical condition: corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) AT (Completed) FR (Completed) NO (Completed) SE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PT (Completed) HU (Completed) BG (Completed) PL (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003412-37 Sponsor Protocol Number: 323/12 Start Date*: 2015-08-10
    Sponsor Name:Keele University
    Full Title: Improving outcomes for patients with hip osteoarthritis: a randomised controlled trial
    Medical condition: Hip osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003653-16 Sponsor Protocol Number: S62092 Start Date*: 2019-03-21
    Sponsor Name:UZ Leuven
    Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study
    Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10072959 Birdshot chorioretinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001492-37 Sponsor Protocol Number: Z-AMD Start Date*: 2019-11-01
    Sponsor Name:Oslo University Hospital
    Full Title: Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized controlled pilot study
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003162-41 Sponsor Protocol Number: ET2012000058 Start Date*: 2013-01-21
    Sponsor Name:Centre Léon Bérard
    Full Title: A randomized, multicenter, open-label, phase II study of the optimal scheme of administration of pazopanib in thyroid carcinoma
    Medical condition: Iodine refractory Differentiated Thyroid Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10043702 Thyroid carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002887-26 Sponsor Protocol Number: CRAD001T2302 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ...
    Medical condition: Advanced neuroendocrine tumor (NET) of GI or lung origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (Completed) IT (Completed) NO (Completed) NL (Completed) GR (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004332-30 Sponsor Protocol Number: ET18-291 Start Date*: 2020-04-24
    Sponsor Name:Centre Léon Bérard
    Full Title: LENVAGIST - A multicentre, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imati...
    Medical condition: Patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib (either on 3rd line treatment or beyond a 3rd line with regorafenib)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004359-35 Sponsor Protocol Number: ICEA2020.1 Start Date*: 2020-10-23
    Sponsor Name:Leiden University Medical Center
    Full Title: Induction of Cure in Early Arthritis
    Medical condition: early unclassified arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10062164 Seronegative arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004432-38 Sponsor Protocol Number: CINC424D2301 Start Date*: 2017-10-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cel...
    Medical condition: corticosteroid refractory chronic Graft vs Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10072158 Chronic graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10072159 Chronic graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    20.1 10021428 - Immune system disorders 10072160 Chronic graft versus host disease in liver PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) DK (Completed) NL (Completed) IT (Completed) FR (Completed) PT (Completed) HU (Completed) PL (Completed) BG (Completed) NO (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004409-30 Sponsor Protocol Number: PS-CLL-009 Start Date*: 2021-05-27
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL)
    Medical condition: Previously Untreated Chronic Lymphophatic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002569-20 Sponsor Protocol Number: BIELEFELD-Janssen-PHRCN-2017 Start Date*: 2018-11-06
    Sponsor Name:CHU Dijon Bourgogne
    Full Title: A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of ustekinumab in association with prednisone, for the treatment of non-infectious severe uveitis (NISU)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001544-31 Sponsor Protocol Number: PATP1001 Start Date*: 2007-04-12
    Sponsor Name:Moorfields Eye Hospital
    Full Title: A randomised, double-masked, phase 3 study of the efficacy and safety of Avastin® (bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovasculariza...
    Medical condition: Exudative age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-006141-19 Sponsor Protocol Number: UMCG-RR#202000930 Start Date*: 2021-05-21
    Sponsor Name:University Medical Center Groningen
    Full Title: Fluorescence guided surgery for intra-operative detection of meningioma using Bevacizumab-IRDye800CW
    Medical condition: meningioma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027191 Meningioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005154-44 Sponsor Protocol Number: OPERA Start Date*: 2006-03-02
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC Open, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatme...
    Medical condition: metastasized colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002976-32 Sponsor Protocol Number: unknown Start Date*: 2007-09-06
    Sponsor Name:TIPharma
    Full Title: COBRA-light study, an open randomised trial comparing a modified COBRA therapy with the COBRA therapy according to BeSt in early rheumatoid arthritis.
    Medical condition: Patients with early rheumatoid arthritis wil be treated with a combination therapy: COBRA according to BEST or a modified COBRA schedule (COBRA-light).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001363-22 Sponsor Protocol Number: TH-CR-302 Start Date*: 2004-12-10
    Sponsor Name:Threshold Pharmaceuticals
    Full Title: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
    Medical condition: Previously treated metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10033599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006233-40 Sponsor Protocol Number: CRFB002ADE04 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology, Bonn University
    Full Title: Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every ...
    Medical condition: Typical findings in Type 2 idiopathic macular telangiectasia (type2-IMT)are parafoveal ectatic capillaries, The disease is characterized by a slow decrease in visual acuity, reading difficulties an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064761 Parafoveal telangiectasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003577-34 Sponsor Protocol Number: 2022/702 Start Date*: 2023-01-30
    Sponsor Name:CHU de Besancon
    Full Title: Induction regorafenib in combination with metronomic cyclophosphamide, capecitabine and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer. An open-label randomiz...
    Medical condition: cancer colorectal métastatique
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004318-14 Sponsor Protocol Number: NEOD001-201 Start Date*: 2016-06-13
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA